Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.47 |
| ▸ | GABRD | O14764 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.47 |
| ▸ | GABRE | P78334 | 1/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.47 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.47 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.47 |
| ▸ | NNMT | P40261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MLYCD | O95822 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10460373 | 0.84 | MLYCD (0.48) | MLYCDMC4RF2F10F7 | |
| SCHEMBL13691952 | 0.83 | MLYCD (0.41) | MLYCDHDAC1HDAC6MC4RF2 | |
| SCHEMBL5312194 | 0.80 | SMN1; SMN2 (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL13691959 | 0.79 | OPRK1 (0.34) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10726188 | 0.76 | GABRP (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL12156556 | 0.75 | MLYCD (0.43) | MLYCDMC4RF2F10F7 | |
| SCHEMBL611496 | 0.74 | SMN1; SMN2 (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL13450864 | 0.73 | EPHX2 (0.69) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL12425360 | 0.73 | OPRM1 (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL12687787 | 0.73 | MLYCD (0.44) | MLYCDF2F10F7LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236818-B2 | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-8236818-B2 | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-8236818-B2 | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-20100324036-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-12-23 | — | — | US | disclosed |
| US-20100324036-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-12-23 | — | — | US | disclosed |
| US-20100093697-A1 | Substituted Imidazopyridine Derivatives As Melanocortin-4 Receptor Antagonists | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100093697-A1 | Substituted Imidazopyridine Derivatives As Melanocortin-4 Receptor Antagonists | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100093697-A1 | Substituted Imidazopyridine Derivatives As Melanocortin-4 Receptor Antagonists | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-04-15 | — | — | US | disclosed |
| WO-2010034500-A1 | SUBSTITUTED IMIDAZOPYRIDINE, IMIDAZOPYRAZINE, IMIDAZOPYRIDAZINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010034500-A1 | SUBSTITUTED IMIDAZOPYRIDINE, IMIDAZOPYRAZINE, IMIDAZOPYRIDAZINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-04-01 | — | — | WO | disclosed |
| EP-2168965-A1 | Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2010-03-31 | — | — | EP | disclosed |
| EP-2168965-A1 | Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2010-03-31 | — | — | EP | disclosed |
| EP-2144907-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| WO-2009080291-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| EP-2072516-A1 | Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2009-06-24 | — | — | EP | disclosed |
| WO-2008116665-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116665-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-10-02 | — | — | WO | disclosed |
| EP-1974729-A1 | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2008-10-01 | — | — | EP | disclosed |
| EP-1974729-A1 | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2008-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324036-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | MC4R, MC5R, MC3R | GABRP 839/4885GABRD 784/4885GABRA1 994/4885 |
| US-20100093697-A1 | Substituted Imidazopyridine Derivatives As Melanocortin-4 Receptor Antagonists | MC4R, MC3R, MC5R | GABRP 474/4885GABRD 376/4885GABRA1 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.